

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Regeneron Pharmaceuticals, Inc.,
Petitioner

v.

Novartis Pharma AG,
Novartis Technology LLC,
Novartis Pharmaceuticals Corporation,
PATENT Owner

IPR2020-01317
Patent 9,220,631 B2

Mailed: June 1, 2021

NOTICE OF REFUND

Petitioner's request for a refund of certain post-institution fees paid on July 16, 2020, in the above proceeding is hereby granted. The amount of \$21,600.00 has been refunded to Petitioner's deposit account.

The parties are reminded that unless otherwise permitted by 37 C.F.R. § 42.6(b)(2), all filings in this proceeding must be made electronically in the Patent Trial and Appeal Board End to End (PTAB E2E), accessible from the Board Web site at <http://www.uspto.gov/PTAB>.

IPR2020-01317
Patent 9,220,631 B2

If there are any questions pertaining to this notice, please contact the
Patent Trial and Appeal Board at 571-272-7822.

IPR2020-01317
Patent 9,220,631 B2

PETITIONER:

Elizabeth Weiswasser
elizabeth.weiswasser@weil.com
Anish Desai
anish.desai@weil.com
Brian Ferguson
brian.ferguson@gweil.com
Christopher Pepe
christopher.pepe@weil.com

PATENT OWNER:

Elizabeth J. Holland
eholland@goodwinlaw.com
William G. James
wjames@goodwinlaw.com
Linnea Cipriano
lcipriano@goodwinlaw.com
Joshua Weinger
jweinger@goodwinlaw.com